Project Updates

Pfizer

Credit: Pfizer

Location: Grange Castle, Clondalkin, Ireland
Project type: Biotech production plant
Expected Completion: 2027
Estimated Investment: $1.26 bn

Pfizer will invest more than €1.2bn ($1.26bn) to build a new facility in the site premises to double the biological drug substance manufacturing capacity of the campus. Construction work is expected to begin in 2024 and will complete in 2027.

Eminence

Credit: Eminence

Location: Suzhou, China 
Project type:
GMP cell culture media manufacturing facility 
Opening date: September 2023 
Size: 7,000m²

Eminence Biotechnology, a cell culture solutions provider based in China, opened a good manufacturing practice (GMP)-certified facility in Suzhou, China, in September 2023, to manufacture cell culture media on a commercial scale. The state-of-the-art facility covers a 7,000m² area.

ReiThera

Credit: ReiThera

Location: Castel Romano Technopole, Italy
Project type: Viral Vector Production Facility Expansion 
Construction start: May 2020 
Estimated investment: €15m ($14.6m)

ReiThera, a contract development and manufacturing organisation based in Italy, has expanded its viral production operations facility to meet the demand for viral vectors globally. The expansion included the construction of a specialised production area which opened in May 2020.

Go to article: Home | Advancing islet transplantation for type 1 diabetesGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Endress+HauserGo to article: Dr. Paul LohmannGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: NiproGo to article: Bio Image SystemsGo to article: In DepthGo to article: Islet transplantation for type 1 diabetes: Do regulators have it right?Go to article: DCT Tracker: Are sponsors getting better at conducting DCTs? Go to article: Why are haemophilia gene therapies so expensive? Go to article: Non-viral vectors could alleviate gene therapy capacity crunchGo to article: Q&A: ‘Trial failure due to recruitment is a thing of the past thanks to AI’ Go to article: NatoliGo to article: Pfeiffer VacuumGo to article: ListingsGo to article: EventsGo to article: AwardsGo to article: Buyer's GuidesGo to article: Next issue